Table 4.

Published results of clinical trials on the use of CD47 antagonists in hematological tumors

Drug Name	NCT Number	Sponsor	Protocol	Indication Detail	Enroll-ment	Age/Race/Healthy Volunteers	Phase	Status	Start Date	Design	Endpoint Types	Efficacy Results	Ref
CC-90002	NCT02641002	Celgene Corp	CC-90002	Subjects With AML and High-Risk MDS	28	Adults (18 and over)	Phase I	Terminted	2016/3/1	Interventional; Treatment; Open Label; Single Group Assignment	Safety; Efficacy; Pharmacokinetics	terminated (preliminary monotherapy data did not offer a sufficiently encouraging profile for further dose escalation/expansion)	[61]
TJ011133	NCT04202003	I-Mab Biopharma Co Ltd	TJ011133	r/r AML/MDS	5	Adults (18–79 years)	Phase I	Recruiting	2020/3/25	Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment	Efficacy	20% achieved morphologic leukemia-free state	[62]
Hu5F9-G4	NCT03248479	Gilead Sciences Inc	Hu5F9-G4; AZA	untreated AML/MDS	68	Adults (18 and over)	Phase I	Recruiting	2017/9/8	Interventional; Treatment; Non-Randomized; Open Label; Parallel Assignment	Safety; Efficacy; Pharmacokinetics	ORR: 79%; CR/CRi: 56%	[63]
Hu5F9-G4	NCT04435691	MD Anderson Cancer Center	Hu5F9-G4; AZA; VEN	Patients (pts) with Newly Diagnosed AML	23	Adults (18 and over)	Phase I/II	Recruiting	2020/7/28	Interventional; Treatment; Open Label; Single Group Assignment	Safety; Efficacy	CR/CRi: 100%	[64]
Hu5F9-G4	NCT04435691	MD Anderson Cancer Center	Hu5F9-G4; AZA; VEN	Patients (pts) with R/R-post-VEN failure AML	13	Adults (18 and over)	Phase I/II	Recruiting	2020/7/28	Interventional; Treatment; Open Label; Single Group Assignment	Safety; Efficacy	CR/CRi: 27%	[64]
Hu5F9-G4	NCT04435691	MD Anderson Cancer Center	Hu5F9-G4; AZA; VEN	Patients (pts) with R/R-VEN naive AML	8	Adults (18 and over)	Phase I/II	Recruiting	2020/7/28	Interventional; Treatment; Open Label; Single Group Assignment	Safety; Efficacy	CR/CRi: 63%	[64]